Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Director | March 02, 2026 | March 04, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Director · Executive Chair | November 07, 2022 | November 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eikon Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.88 · Expires 2036-03-01 | Direct | 25,873 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 25,873 · Balance 25,873 F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Merck & Co., Inc.
Report date November 07, 2022 · Filed November 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 936,422.063 |
Reported balance
After 2022-11-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-07 · Exercise / conversion · Acquired 235,769 · Balance 936,422.063 |
| Common StockSEC Table I · non-derivative | Direct | 911,508.063 |
Reported balance
After 2022-11-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-07 · Sale · Disposed 24,914 · Balance 911,508.063 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 785,374.063 |
Reported balance
After 2022-11-07 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2022-11-07 · Sale · Disposed 126,134 · Balance 785,374.063 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 700,653.063 |
Reported balance
After 2022-11-07 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2022-11-07 · Sale · Disposed 84,721 · Balance 700,653.063 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F4: Holdings include shares acquired in dividend reinvestment transactions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.06 · Expires 2026-05-09 | Direct | 0 |
Reported balance
After 2022-11-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-07 · Exercise / conversion · Disposed 235,769 · Balance 0 F6: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy 401(k) | 4,481.1286 |
Reported balance
Holding disclosure · report date 2022-11-07 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 4,481.1286 F5: Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F4: Holdings include shares acquired in dividend reinvestment transactions.
F5: Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.
F6: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EXXON MOBIL CORP
Report date May 25, 2022 · Filed May 26, 2022
Section 16 reporting ended · disclosed 2022-05-26. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2018 Filed Mar 2, 2018 00:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 110,393 | $54.72 | $6,040,704.96 |
DisclosureSEC source: 0001225208-18-005010 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,697.063 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:53 UTC | EXXON MOBIL CORP XOM · Entity 32533 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-000979 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 F1 · price: Restricted stock grant. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 534,950 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009427 · doc4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,950 Underlying: Common Stock · 534,950 shares Expires 2027-05-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 101,552 | $65.85 | $6,687,199.20 |
DisclosureSEC source: 0001225208-17-005085 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,304.063 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 07, 2017 Filed Mar 1, 2017 21:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 10,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005085 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 498,752.063 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:56 UTC | EXXON MOBIL CORP XOM · Entity 32533 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-000994 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · price: Restricted stock grant. Read SEC document |
| November 10, 2016 Filed Nov 10, 2016 22:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 133,920 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001225208-16-041461 · doc4.xml · derivative · entry 7 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133,920 shares Expires 2019-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 4/24/2010, 4/24/2011 and 4/24/2012. Read SEC document |
| November 10, 2016 Filed Nov 10, 2016 22:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 133,920 | $65.03 | $8,709,286.32 |
DisclosureSEC source: 0001225208-16-041461 · doc4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,877.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.0000 to $65.1900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 10, 2016 Filed Nov 10, 2016 22:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 133,920 | $23.45 | $3,140,424.00 |
DisclosureSEC source: 0001225208-16-041461 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 642,797.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 22:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 6,080 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001225208-16-041461 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,920 Underlying: Common Stock · 6,080 shares Expires 2019-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 4/24/2010, 4/24/2011 and 4/24/2012. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 22:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 6,080 | $65.00 | $395,200.00 |
DisclosureSEC source: 0001225208-16-041461 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,877.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 22:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 6,080 | $23.45 | $142,576.00 |
DisclosureSEC source: 0001225208-16-041461 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,957.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2016 Filed Aug 5, 2016 21:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001225208-16-037553 · doc4.xml · derivative · entry 8 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2019-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option became exercisable in equal installments on 4/24/2010, 4/24/2011 and 4/24/2012. Read SEC document |
| August 05, 2016 Filed Aug 5, 2016 21:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 252,000 | $0.00 Strike: $44.30 | $0.00 |
DisclosureSEC source: 0001225208-16-037553 · doc4.xml · derivative · entry 7 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 252,000 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 2/28/2009, 2/28/2010 and 2/28/2011. Read SEC document |
| August 05, 2016 Filed Aug 5, 2016 21:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 232,952 | $61.54 | $14,335,074.04 |
DisclosureSEC source: 0001225208-16-037553 · doc4.xml · nonDerivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,877.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.3000 to $61.9200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F4 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 05, 2016 Filed Aug 5, 2016 21:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 140,000 | $62.24 | $8,713,600.00 |
DisclosureSEC source: 0001225208-16-037553 · doc4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,829.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 05, 2016 Filed Aug 5, 2016 21:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 19,048 | $62.08 | $1,182,421.74 |
DisclosureSEC source: 0001225208-16-037553 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,829.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.0100 to $62.3800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 05, 2016 Filed Aug 5, 2016 21:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 140,000 | $23.45 | $3,283,000.00 |
DisclosureSEC source: 0001225208-16-037553 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,877.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2016 Filed Aug 5, 2016 21:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 252,000 | $44.30 | $11,163,600.00 |
DisclosureSEC source: 0001225208-16-037553 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760,877.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2016 Filed Aug 3, 2016 18:52 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 13,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-037429 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,877.063 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| July 05, 2016 Filed Jul 5, 2016 16:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 27,621 | $0.00 Strike: $51.02 | $0.00 |
DisclosureSEC source: 0001225208-16-036059 · doc4.xml · derivative · entry 7 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,621 shares Expires 2017-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 8/1/2008, 8/1/2009 and 8/1/2010. Read SEC document |
| July 05, 2016 Filed Jul 5, 2016 16:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 27,621 | $58.00 | $1,602,018.00 |
DisclosureSEC source: 0001225208-16-036059 · doc4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,477.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| July 05, 2016 Filed Jul 5, 2016 16:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 27,621 | $51.02 | $1,409,223.42 |
DisclosureSEC source: 0001225208-16-036059 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,098.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2016 Filed Jul 5, 2016 16:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 32,379 | $0.00 Strike: $51.02 | $0.00 |
DisclosureSEC source: 0001225208-16-036059 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,621 Underlying: Common Stock · 32,379 shares Expires 2017-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 8/1/2008, 8/1/2009 and 8/1/2010. Read SEC document |
| July 01, 2016 Filed Jul 5, 2016 16:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 32,379 | $58.00 | $1,877,982.00 |
DisclosureSEC source: 0001225208-16-036059 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,477.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 01, 2016 Filed Jul 5, 2016 16:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 32,379 | $51.02 | $1,651,976.58 |
DisclosureSEC source: 0001225208-16-036059 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,856.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2016 Filed May 12, 2016 15:39 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 814,941 | $0.00 Strike: $54.68 | $0.00 |
DisclosureSEC source: 0001225208-16-033205 · doc4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 814,941 Underlying: Common Stock · 814,941 shares Expires 2026-05-09 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| April 14, 2016 Filed Apr 14, 2016 18:25 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 131,040 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-16-031436 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 131,040 shares Expires 2017-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 3/2/2008, 3/2/2009 and 3/2/2010. Read SEC document |
| April 14, 2016 Filed Apr 14, 2016 18:25 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 131,040 | $56.11 | $7,352,942.69 |
DisclosureSEC source: 0001225208-16-031436 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,477.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.0000 to $56.2300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 14, 2016 Filed Apr 14, 2016 18:25 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 131,040 | $44.19 | $5,790,657.60 |
DisclosureSEC source: 0001225208-16-031436 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,517.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2016 Filed Feb 24, 2016 17:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 93,241 | $50.77 | $4,733,845.57 |
DisclosureSEC source: 0001225208-16-027759 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,477.063 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance share units granted on 03/29/2013. Performance shares were paid out at 105 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 03, 2015 Filed Nov 4, 2015 21:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-15-020377 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,236.063 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 29, 2015 Filed Oct 30, 2015 20:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 18,666 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-15-020111 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,666 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 3/3/2007, 3/3/2008 and 3/3/2009. Read SEC document |
| October 29, 2015 Filed Oct 30, 2015 20:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 18,666 | $54.69 | $1,020,757.68 |
DisclosureSEC source: 0001225208-15-020111 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,236.063 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.6200 to $54.8000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 29, 2015 Filed Oct 30, 2015 20:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 18,666 | $35.09 | $654,989.94 |
DisclosureSEC source: 0001225208-15-020111 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,902.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 743,034 | $0.00 Strike: $59.86 | $0.00 |
DisclosureSEC source: 0001225208-15-011280 · doc4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743,034 Underlying: Common Stock · 743,034 shares Expires 2025-04-30 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| February 23, 2015 Filed Feb 25, 2015 16:26 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 84,836 | $58.30 | $4,945,938.80 |
DisclosureSEC source: 0001225208-15-005601 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,236.063 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/30/2012. Performance shares were paid out at 102 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 18, 2015 Filed Feb 18, 2015 21:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 7,082 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-15-004508 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,082 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 2/25/2006, 2/25/2007 and 2/25/2008. Read SEC document |
| February 18, 2015 Filed Feb 18, 2015 21:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 5,164 | $58.67 | $302,958.97 |
DisclosureSEC source: 0001225208-15-004508 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,400.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.6001 to $58.7600, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 18, 2015 Filed Feb 18, 2015 21:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 7,082 | $31.84 | $225,490.88 |
DisclosureSEC source: 0001225208-15-004508 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,564.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2015 Filed Jan 9, 2015 19:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,333 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-15-001128 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,666 Underlying: Common Stock · 9,333 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 3/3/2007, 3/3/2008 and 3/3/2009. Read SEC document |
| January 09, 2015 Filed Jan 9, 2015 19:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,541 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-15-001128 · doc4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,082 Underlying: Common Stock · 3,541 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 2/25/2006, 2/25/2007 and 2/25/2008. Read SEC document |
| January 09, 2015 Filed Jan 9, 2015 19:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 8,840 | $62.47 | $552,266.62 |
DisclosureSEC source: 0001225208-15-001128 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,482.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.1900 to $62.7000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 09, 2015 Filed Jan 9, 2015 19:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,541 | $31.84 | $112,745.44 |
DisclosureSEC source: 0001225208-15-001128 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,322.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2015 Filed Jan 9, 2015 19:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,333 | $35.09 | $327,494.97 |
DisclosureSEC source: 0001225208-15-001128 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,781.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2014 Filed Dec 10, 2014 22:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,333 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-14-024749 · doc4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,999 Underlying: Common Stock · 9,333 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 3/3/2007, 3/3/2008 and 3/3/2009. Read SEC document |
| December 10, 2014 Filed Dec 10, 2014 22:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,541 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-14-024749 · doc4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,623 Underlying: Common Stock · 3,541 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 2/25/2006, 2/25/2007 and 2/25/2008. Read SEC document |
| December 10, 2014 Filed Dec 10, 2014 22:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 9,846 | $60.00 | $590,760.00 |
DisclosureSEC source: 0001225208-14-024749 · doc4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,448.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 10, 2014 Filed Dec 10, 2014 22:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,541 | $31.84 | $112,745.44 |
DisclosureSEC source: 0001225208-14-024749 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,294.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2014 Filed Dec 10, 2014 22:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,333 | $35.09 | $327,494.97 |
DisclosureSEC source: 0001225208-14-024749 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,753.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.